Monsanto Beats, Guides High - Analyst Blog


Monsanto Company ( MON ) posted a strong financial result in the first quarter of fiscal 2012 with an EPS (excluding restructuring expense) of 23 cents, breezing past a meager 2 cents recorded a year ago. The result exceeded the Zacks Consensus Estimate of 19 cents.

The company generated revenues of $2,439 million, up from $1,836 million registered in the year-ago quarter. The revenue exceeded the Zacks Consensus Estimate of $2,034 million based on improved sales in the growing Latin America market. 

On a segmental basis, revenues from the Seeds and Genomics segment was recorded at $1,534 million, up 32% compared with $1,163 million in the year-ago quarter.

The segment's improved result was driven by volume growth and a mix benefit from significant corn trait expansion in Brazil and Argentina. Benefits from the Australian cotton business added to the perk. Agricultural Productivity segment's revenues came in at $905 million versus $673 million a year ago.

During the quarter, gross margin was recorded at approximately 45%, in line with that of the year-ago comparable quarter.

Selling, general and administrative expenses were up 11.1% year over year to $500 million. Research & Development (R&D) grew 15.8% year over year to $351 million.

Cash and cash equivalents at the end of 1Q12 were approximately $3,007 million as of November 30, 2011 versus $2,572 million as of August 31, 2011. Long-term debt was recorded at $1,542 million, down marginally from $1,543 million at the end of the previous sequential quarter.

Net Cash provided by Operating Activities was recorded at $1,110 million versus $624 million, a year ago.

Free cash flow increased to $856 million during the quarter ended November 30, 2011 compared with $500 million reported a year ago.


Management affirmed its free cash flow guidance for fiscal 2012 in the range of $1.3 billion to $1.5 billion, reflecting an investment of $600 to $700 million in capital expenditures. 

For fiscal 2012, the company expects net cash provided by operating activities to be $2.2 billion to $2.5 billion, and net cash required by investing activities to be approximately $900 million to $1 billion.

The company guided high on full-year 2012 ongoing EPS, expecting to achieve $3.39 to $3.44 of ongoing and as-reported EPS. 

Going forward, a strong US Order book coupled with a pipeline of advanced R&D appears to add momentum to the stock.

During early December 2011, Monsanto Company declared a quarterly dividend on its common stock of $0.30 per share. The dividend will be payable on January 27, 2012 to shareowners of record as of January 6, 2012. 

Monsanto Company is a leading global provider of agricultural products for farmers, operating in Seeds and Genomics and Agricultural Productivity segments. Monsanto's biotechnology research and innovations position it as a market leader above its peers, such as Syngenta AG ( SYT ) and The Dow Chemical Company ( DOW ).

We currently maintain a long-term Outperform recommendation on the stock. Monsanto has a Zacks #2 Rank, which translates into a short-term Buy rating (1-3 months).

DOW CHEMICAL ( DOW ): Free Stock Analysis Report
MONSANTO CO-NEW ( MON ): Free Stock Analysis Report

SCOTTS MIRCL-GR ( SMG ): Free Stock Analysis Report
SYNGENTA AG-ADR ( SYT ): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: DOW , MON , SMG , SYT

More from

Related Videos




Most Active by Volume

  • $6.975 ▲ 47.78%
  • $10.4464 ▼ 5.12%
  • $15.78 ▲ 0.19%
  • $13.581 ▲ 0.90%
  • $5.75 ▲ 1.23%
  • $110.3343 ▲ 0.76%
  • $27.965 ▼ 0.23%
  • $7.82 ▲ 0.90%
As of 10/9/2015, 10:02 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by